Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Label indication Xofigo is indicated for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease. Xofigo is an alpha particle-emitting radioactive therapeutic agent indicated for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease. ( 1 ) FDA label
Radium Ra 223 dichloride · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Radium Ra 223 dichloride | EXPERIMENTAL | Radium Ra 223 dichloride (Xofigo, BAY88-8223) |
| Name | Type | Description |
|---|---|---|
| Radium Ra 223 dichloride (Xofigo, BAY88-8223) | DRUG | 50 kBq/kg intravenous injection once every 4 weeks, will be administrated from cycle 2 up to 6 cycles |
| paclitaxel | DRUG | 90 mg/m2 intravenous injection per week in a 3-week-on / 1-week-off regimen, will be administered as per local standard of care, starting in cycle 1 |
Inclusion Criteria: * Male or female patients ≥ 18 years of age * Subjects diagnosed with histologically or cytologically confirmed malignant solid tumors and at least two according bone lesions. A standard of practice bone scan for the documentation of at least 2 bone lesions can be used as long a...
Top 14 of 16 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | Luspatercept, Fedratinib, BMS-986158 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, ABBV-744, IMGN632 |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 2 | PHASE3 | Elritercept |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Incyte Corporation | INCY | 8 | PHASE2 | Ruxolitinib, INCB160058, INCB057643, INCA033989, INCA036978 |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| GSK plc Sponsored ADR | GSK | 3 | PHASE2 | Momelotinib |
| Eli Lilly and Company | LLY | 2 | PHASE1 | LY3410738, LY5830966 |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Damora Therapeutics, Inc. | DMRA | 2 | PHASE2 | GB2064, DMR-001 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| Syndax Pharmaceuticals Inc | SNDX | 1 | PHASE1 | Revumenib |
Radium Ra 223 dichloride is an investigational small molecule oncology therapy developed by Bayer AG (ticker BAYRY). It has been studied in patients with neoplasms and bone lesions, specifically in a Phase 1 trial combining it with paclitaxel. It is also known by the names Xofigo and BAY88-8223.
Radium Ra 223 dichloride has been studied for use in patients with neoplasms and bone lesions. The only clinical trial listed for this drug evaluated it in combination with paclitaxel in cancer subjects with bone lesions. It is not approved for any indication based on the available data.
Radium Ra 223 dichloride is developed by Bayer AG, which trades under the ticker BAYRY. Bayer is the sponsor of the Phase 1 trial that studied this drug in combination with paclitaxel in cancer patients with bone lesions.
Radium Ra 223 dichloride is in Phase 1 clinical development. The only trial on record is a completed Phase 1 study. There are no active trials listed for this drug. It is investigational and has not been approved for any indication.
Radium Ra 223 dichloride has been studied in one completed Phase 1 trial, NCT02442063, titled "Phase Ib Study of Radium Ra 223 Dichloride in Combination With Paclitaxel in Cancer Subjects With Bone Lesions." The trial enrolled 15 patients across Finland, Israel, and the United Kingdom.
Yes, Radium Ra 223 dichloride is also known as Xofigo and by the code name BAY88-8223. These names refer to the same drug developed by Bayer AG. The alternative names are used interchangeably in prescribing and research contexts.